期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

AL型淀粉样变性的治疗 被引量：5

Progression of treatment on AL amyloidosis
下载PDF
导出
摘要 AL型淀粉样变性是由于单克隆浆细胞产生异常折叠轻链在组织器官沉积而导致的一种系统性疾病,通常预后较差。以化疗及干细胞移植治疗为主。本文就近年来治疗方面的进展作一简述。 Immunoglobulin light chain amyloidosis （AL） is a systematic disease caused by clonal plasma cells that produce misfolded light chains, which deposit in tissues and organs. Patients often have a poor prognosis. The main treatments are chemotherapy and hematopoietic stem cell transplantation. This article will review the progresses of treatments in recent years.
作者 陈文萃 王庆文
机构地区 南京军区南京总医院 全军肾脏病研究所
出处 《肾脏病与透析肾移植杂志》 CAS CSCD 北大核心 2012年第6期561-566,570,共7页 Chinese Journal of Nephrology,Dialysis & Transplantation
关键词 AL型淀粉样变性造血干细胞移植治疗 AL amyloidosis hematopoietic stem cell transplantation treatment progression
分类号 R692.9 [医药卫生—泌尿科学]
  • 相关文献

参考文献42

  • 1Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood, 1992,79 (7) : 1817 - 1822. 被引量：1
  • 2Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non- canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A ,2010, 107(9) :4188 -4193. 被引量：1
  • 3Sanchorawala V, Wright DG, Seldin DC, et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis:resuhs of a prospective randomized trial. Bone Marrow Transplant,2004,33 (4) :381 - 388. 被引量：1
  • 4Perz JB, Schonland SO, Hundemer M, et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase 11 study. BrJ Haematol,2004,i27(5) :543 -551. 被引量：1
  • 5Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood ,2004,103 ( 8 ) :2936 - 2938. 被引量：1
  • 6Bellavia D, Pellikka PA, A1-Zahrani GB, et al. Independent predictorsof survival in primary systemic (AI) amyloidosis, including cardiac biomarkers and left ventricular strain imaging:an observational cohort study. J Am Soc Echocardiogr, 2010,23 ( 6 ) : 643 - 652. 被引量：1
  • 7Dietrich S, Schnland SO, Benner A, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood, 2010, 116 ( 4 ) : 522 - 528. 被引量：1
  • 8Lebovic D,Hoffman J,Levine BM,et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haemato1,200 ,143(3) :369 -373. 被引量：1
  • 9Dispenzieri A, Lacy MQ, Rajkumar SV, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid,2003,10 ( 4 ) : 257 - 261. 被引量：1
  • 10Wechalekar AD, Goodman H J, Lachmann H J, et al. Safety and efficac of risk-adapted cyclophosphamide, thalidomide, and dexamethasone systemic AL amyloidosis. Blood, 2007,109 ( 2 ) :457 - 464. 被引量：1

二级参考文献45

  • 1翟勇平,宋萍,唐玉梅,于亚平,刘海宁,卢晓洵,杨敏,王学文.自体外周血干细胞移植治疗原发性系统性淀粉样变性二例报告并文献复习[J].中华血液学杂志,2007,28(5):346-348. 被引量：4
  • 2Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood, 2002,99:4276-4282. 被引量：1
  • 3Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant, 2001, 28: 637-642. 被引量：1
  • 4Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis(AL) : a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol, 2005,79:319-328. 被引量：1
  • 5Gertz MA, Lacy MQ, Lust JA, et al. Prospective randomised trial of melphalan and prednisone versus vineristine, earmustine, melphalan, eyclophosphamide and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol, 1999, 17:262-267. 被引量：1
  • 6Lachmann HJ, Gillmore JD, Pepys M, et al. Outcome in systemic AL amyloidosis following stem cell transplantation or infusional chemotherapy. Blood, 2002, 100: 210a. 被引量：1
  • 7Palladini G, Anesi E, Perfetti V, et al. Amodified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol, 2001,113 : 1044-1046. 被引量：1
  • 8Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood, 2004,103:2936-2938. 被引量：1
  • 9Dhodapkar MV, Hussein MA, Rasmussen E, et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/a interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood, 2004,104:3520-3526. 被引量：1
  • 10Dispenzieri A, Lacy MQ, Rajkumar SV, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid, 2003,10:257-261. 被引量：1

共引文献11

同被引文献60

引证文献5

二级引证文献6

肾脏病与透析肾移植杂志
2012年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部